lncRNA-ATB/miR-141-3p/GP73轴介导EMT促进TACE抵抗的研究进展
Research Progress of lncRNA-ATB/miR-141-3p/GP73 Ax-is-Mediated EMT Promoting TACE Refractoriness
DOI: 10.12677/ACM.2024.141128, PDF,    国家自然科学基金支持
作者: 耿 棋, 朱帝文, 任伟新*：新疆医科大学第一附属医院介入放射科，新疆 乌鲁木齐
关键词: 肝癌；经导管动脉化疗栓塞抵抗；GP73；lncRNA-ATB；miR-141-3p；Liver Cancer； TACE Refractoriness； GP73； lncRNA-ATB； miR-141-3p
摘要: 经导管动脉化疗栓塞(TACE)广泛应用于中晚期肝癌的治疗。然而，反复的TACE治疗并非总能对预后产生积极影响，部分学者将此现象称为TACE抵抗。由于定义的模糊和关键性证据不足，TACE抵抗的概念尚存争议。前有研究表明，上皮–间充质转化(EMT)是肝癌复发转移的重要原因，而肝癌的转移或许是TACE抵抗发生的潜在机制之一，故本文主要讨论TACE抵抗的相关研究，特别关注了GP73、miR-141-3p、lncRNA-ATB等介导EMT潜在促使TACE抵抗发生的研究进展，期望为中晚期肝癌治疗提供新靶点和理论基础。
Abstract: Transcatheter arterial chemoembolization (TACE) is widely used in the treatment of advanced liver cancer. However, repeated TACE treatment does not always have a positive effect on prognosis, some scholars refer to this phenomenon as TACE refractoriness. The concept of TACE refractoriness remains controversial due to vague definitions and lack of critical evidence. Previous studies have shown that epithelial-mesenchymal transformation (EMT) is an important cause of liver cancer re-currence and metastasis, and liver cancer metastasis may be one of the potential mechanisms of TACE refractoriness. Therefore, this paper mainly discusses relevant studies on TACE refractoriness. Special attention was paid to the research progress of GP73, miR-141-3p, lncRNA- ATB, etc. mediat-ing EMT and potentially promoting TACE refractoriness, hoping to provide new targets and theoret-ical basis for the treatment of middle and advanced liver cancer.
文章引用：耿棋, 朱帝文, 任伟新. lncRNA-ATB/miR-141-3p/GP73轴介导EMT促进TACE抵抗的研究进展[J]. 临床医学进展, 2024, 14(1): 903-910. https://doi.org/10.12677/ACM.2024.141128

参考文献

[1] Philips, C.A., Rajesh, S., Nair, D.C., et al. (2021) Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus, 13, e19274. [Google Scholar] [CrossRef] [PubMed]
[2] Zhong, B.Y., Jiang, J.Q., Sun, J.H., et al. (2023) Prognostic Performance of the China Liver Cancer Staging System in Hepatocellular Carcinoma Following Transarterial Chemoem-bolization. Journal of Clinical and Translational Hepatology, 11, 1321-1328.
[3] Adwan, H., Adwan, M. and Vogl, T.J. (2023) Combination Therapy of Bland Transarterial Embolization and Microwave Ablation for Hepatocellular Car-cinoma within the Milan Criteria Leads to Significantly Higher Overall Survival. Cancers, 15, Article 5076. [Google Scholar] [CrossRef] [PubMed]
[4] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版) [J]. 中华消化外科杂志, 2022, 21(2): 143-168.
[5] Kudo, M. (2022) New Treatment Para-digm with Systemic Therapy in Intermediate-Stage Hepatocellular Carcinoma. International Journal of Clinical Oncology, 27, 1110-1119. [Google Scholar] [CrossRef] [PubMed]
[6] Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2023) 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepa-tocellular Carcinoma. Journal of Liver Cancer, 23, 1-120. [Google Scholar] [CrossRef] [PubMed]
[7] Zhong, B.Y., Jin, Z.C., Chen, J.J., et al. (2023) Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 11, 480-489.
[8] Zhang, S., Wang, W.S., Zhong, B.Y., et al. (2022) Subsequent Treatment after Transarterial Chemoem-bolization Failure/Refractoriness: A Review Based on Published Evidence. Journal of Clinical and Translational Hepa-tology, 10, 740-747. [Google Scholar] [CrossRef] 
[9] Qiu, Z., Shen, L., Chen, S., et al. (2019) Ef-ficacy of Apatinib in Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate and Advanced-Stage Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Cancer Management and Research, 11, 9321-9330. [Google Scholar] [CrossRef] 
[10] Kaibori, M., Matsushima, H., Ishizaki, M., et al. (2021) The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellu-lar Carcinoma. Asian Pacific Journal of Cancer Prevention, 22, 1217-1224. [Google Scholar] [CrossRef] 
[11] 张申, 张磊, 仲斌演, 等. “TACE抵抗/失败”——需要全面认识[J]. 介入放射学杂志, 2020, 29(8): 743-747.
[12] Lee, J.S., Kim, B.K., Kim, S.U., et al. (2020) A Survey on Transarterial Chemoembolization Refractoriness and a Real-World Treatment Pattern for Hepatocellular Carcinoma in Korea. Clinical and Molecular Hepatology, 26, 24-32. [Google Scholar] [CrossRef] [PubMed]
[13] Zhong, B.Y., Wang, W.S., Zhang, S., Zhu, H.D., et al. (2021) Re-Evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventional-ists. Journal of Clinical and Translational Hepatology, 9, 521-527.
[14] 中国医师协会介入医师分会临床诊疗指南专委会. 肝细胞癌经动脉化疗栓塞抵抗及后续治疗专家共识[J]. 中华内科杂志, 2022, 61(8): 860-866.
[15] Kudo, M., Han, K.H., Ye, S.L., et al. (2020) A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Car-cinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer, 9, 245-260. [Google Scholar] [CrossRef] [PubMed]
[16] Liu, Y., Wang, J., Yang, R., et al. (2021) GP73-Mediated Secretion of AFP and GP73 Promotes Proliferation and Metastasis of Hepatocellular Carcinoma Cells. Oncogenesis, 10, Article No. 69. [Google Scholar] [CrossRef] [PubMed]
[17] Liu, L., Huang, Y., Fu, Y., et al. (2022) Hepatitis B Virus Pro-motes Hepatocellular Carcinoma Development by Activating GP73 to Repress the Innate Immune Response. Infectious Agents and Cancer, 17, Article No. 52. [Google Scholar] [CrossRef] [PubMed]
[18] Ali, O.M., El Amin, H.A., Sharkawy, Y.L., et al. (2020) Golgi Protein 73 versus α-Fetoprotein as a New Biomarker in Early Diagnosis of Hepatocellular Carcinoma. International Journal of General Medicine, 13, 193-200. [Google Scholar] [CrossRef] 
[19] 李丹丹, 谭艳, 唐俊明, 等. 细胞上皮间充质转化转化态异质性及可塑性的最新研究进展[J]. 湖北医药学院学报, 2023, 42(2): 216-223.
[20] Manfioletti, G. and Fedele, M. (2022) Epithelial-Mesenchymal Transition (EMT) 2021. International Journal of Molecular Sciences, 23, Article 5848. [Google Scholar] [CrossRef] [PubMed]
[21] 马艳丽, 杨靖, 吕梦丽. KAI1, Snail, Slug, E-cadherin在鼻咽癌组织中的表达及其与患者预后的关系[J]. 实用癌症杂志, 2023, 38(4): 562-564, 568.
[22] 黄兴武, 罗锋, 阳国彬. miR-142-5p通过靶向作用WWP1对前列腺癌细胞PC-3生物学行为的影响[J]. 实用癌症杂志, 2022, 37(7): 1060-1067.
[23] Orrapin, S., Udomruk, S., Lapisatepun, W., et al. (2022) Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review. Cancers, 14, Article 3373. [Google Scholar] [CrossRef] [PubMed]
[24] 覃熙媛, 朱莹, 李伟滔, 等. 上皮性卵巢癌组织中FoxM1的表达及其临床意义[J]. 癌变∙畸变∙突变, 2023, 35(4): 273-278.
[25] Bao, Y.X., Cao, Q., Yang, Y., et al. (2013) Expression and Prognostic Significance of Golgiglycopro-tein73 (GP73) with Epithelial-Mesenchymal Transition (EMT) Related Molecules in Hepatocellular Carcinoma (HCC). Diagnostic Pathology, 8, Article No. 197. [Google Scholar] [CrossRef] [PubMed]
[26] Sun, Y., Yang, H., Mao, Y., et al. (2011) Increased Golgi Protein 73 Expression in Hepatocellular Carcinoma Tissue Correlates with Tumor Ag-gression But Not Survival. Journal of Gastroenterology and Hepatology, 26, 1207-1212. [Google Scholar] [CrossRef] [PubMed]
[27] Yang, Y., Liu, Q., Zhang, H., et al. (2017) Silencing of GP73 Inhibits Invasion and Metastasis via Suppression of Epithelial-Mesenchymal Transition in Hepatocellular Carci-noma. Oncology Reports, 37, 1182-1188. [Google Scholar] [CrossRef] [PubMed]
[28] Chen, J., Ding, Z.Y., Li, S., et al. (2021) Targeting Transforming Growth Factor-β Signaling for Enhanced Cancer Chemotherapy. Theranostics, 11, 1345-1363. [Google Scholar] [CrossRef] [PubMed]
[29] Yang, Y., Liu, Q., Li, Z., et al. (2018) GP73 Promotes Epitheli-al-Mesenchymal Transition and Invasion Partly by Activating TGF-β1/Smad2 Signaling in Hepatocellular Carcinoma. Carcinogenesis, 39, 900-910. [Google Scholar] [CrossRef] [PubMed]
[30] Pan, J., Zhang, Y.F., Yang, H.Y., et al. (2015) The Response of Golgi Protein 73 to Transcatheter Arterial Chemoembolization in Patients with Hepatocellular Carcinoma May Relate to the In-fluence of Certain Chemotherapeutics. Hepatobiliary & Pancreatic Diseases International, 14, 406-412. [Google Scholar] [CrossRef] 
[31] Ai, N., Liu, W., Li, Z.G., et al. (2017) High Expression of GP73 in Primary Hepatocellular Carcinoma and Its Function in the Assessment of Transcatheter Arterial Chemoemboli-zation. Oncology Letters, 14, 3953-3958. [Google Scholar] [CrossRef] [PubMed]
[32] Khare, S., Khare, T., Ramanathan, R. and Ibdah, J.A. (2022) Hepatocel-lular Carcinoma: The Role of MicroRNAs. Biomolecules, 12, Article 645. [Google Scholar] [CrossRef] [PubMed]
[33] Menon, A., Abd-Aziz, N., Khalid, K., et al. (2022) miRNA: A Prom-ising Therapeutic Target in Cancer. International Journal of Molecular Sciences, 23, Article 11502. [Google Scholar] [CrossRef] [PubMed]
[34] Rzeszutek, I. and Singh, A. (2020) Small RNAs, Big Diseases. Inter-national Journal of Molecular Sciences, 21, Article 5699. [Google Scholar] [CrossRef] [PubMed]
[35] Xu, X., Tao, Y., Shan, L., et al. (2018) The Role of MicroRNAs in Hepatocellular Carcinoma. Journal of Cancer, 9, 3557-3569. [Google Scholar] [CrossRef] [PubMed]
[36] Hou, X., Yang, L., Jiang, X., et al. (2019) Role of microRNA-141-3p in the Progression and Metastasis of Hepatocellular Carcinoma Cell. International Journal of Biological Macromolecules, 128, 331-339. [Google Scholar] [CrossRef] [PubMed]
[37] Liu, Y., Ding, Y., Huang, J., et al. (2014) MiR-141 Suppress-es the Migration and Invasion of HCC Cells by Targeting Tiam1. PLOS ONE, 9, e88393. [Google Scholar] [CrossRef] [PubMed]
[38] Ma, L., Shao, H., Chen, H., et al. (2021) The Mechanism of miR-141 Regulating the Proliferation and Metastasis of Liver Cancer Cells by Targeting STAT4. Journal of Oncology, 2021, Article ID: 5425491. [Google Scholar] [CrossRef] [PubMed]
[39] Tao, S., Hou, Y., Diao, L., et al. (2022) Long Noncoding RNA Study: Genome-Wide Approaches. Genes & Diseases, 10, 2491-2510. [Google Scholar] [CrossRef] [PubMed]
[40] Yuan, J.H., Yang, F., Wang, F., Ma, J.Z., et al. (2014) A Long Noncoding RNA Activated by TGF-β Promotes the Invasion-Metastasis Cascade in Hepatocellular Carcinoma. Cancer Cell, 25, 666-681. [Google Scholar] [CrossRef] [PubMed]
[41] Sun, T. and Wong, N. (2015) Transforming Growth Fac-tor-β-Induced Long Noncoding RNA Promotes Liver Cancer Metastasis via RNA-RNA Crosstalk. Hepatology, 61, 722-724. [Google Scholar] [CrossRef] [PubMed]

为你推荐